Catus Consult ApS: Financial statements 2023
CVR: 39791633
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Catus Consult ApS (CVR 39791633) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK 0 compared with DKK 0 the year before. Equity in the 2023 report amounted to DKK 40,000. The solvency ratio was 100%.
- Profit/Loss
- DKK 0
- Equity
- DKK 40,000
- Total Assets
- DKK 40,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | 0 | 40 t. | - |
| 2022 | - | - | 0 | 40 t. | - |
| 2021 | - | 0 | 0 | 40 t. | - |
| 2020 | - | 30 t. | 23 t. | 19 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Catus Consult ApS has published its annual report for 2022. The net result was DKK 0.
About Catus Consult ApS
Catus Consult ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Isanans Pharma ApS and Isanans Pharma IVS. The management consists of Kamilla Rolsted. The company is owned by VAMI Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 680,675 and a net result of DKK 137,824 compared with DKK -7,234 the year before. Equity in the 2025 report amounted to DKK 181,118.